Paul Edward Kelly net worth and biography

Paul Kelly Biography and Net Worth

Paul Kelly has been actively involved as an analyst, consultant and investor in the biotechnology sector for the past thirty years. He has been a Director of the Company since November, 2015. Additionally, he has been acting as a Special Advisor to the Chief Executive Officer of the Company since January 1, 2023. He began as an equity analyst at Mabon Securities in 1993, and later served in the same capacity at UBS Securities, Volpe, Brown, Whalen, ING Securities, and Merrill Lynch. Mr. Kelly was named to the inaugural Fortune Magazine All Star Analyst Team in 2000. Since 2007, Mr. Kelly has engaged in consulting for private and public biotechnology companies and for hedge funds. He currently manages his own investments and continues his industry consulting activities. Mr. Kelly holds an A.B. in biochemistry from Brown University, attended the University of Rochester School of Medicine, and received an M.B.A in finance from the William E. Simon School at the University of Rochester.

What is Paul Edward Kelly's net worth?: The estimated net worth of Paul Edward Kelly is at least $3.34 million as of November 5th, 2025. Kelly owns 502,295 shares of Relmada Therapeutics stock worth more than $3,335,239 as of March 25th. This net worth approximation does not reflect any other assets that Kelly may own. Learn More about Paul Edward Kelly's net worth.
How do I contact Paul Edward Kelly?: The corporate mailing address for Kelly and other Relmada Therapeutics executives is 880 Third Avenue 12th Floor, NEW YORK NY, 10022. Relmada Therapeutics can also be reached via phone at (786) 629-1376 and via email at [email protected]. Learn More on Paul Edward Kelly's contact information.
Has Paul Edward Kelly been buying or selling shares of Relmada Therapeutics?: Paul Edward Kelly has not been actively trading shares of Relmada Therapeutics during the past quarter. Most recently, on Wednesday, November 5th, Paul Edward Kelly bought 90,000 shares of Relmada Therapeutics stock. The stock was acquired at an average cost of $2.20 per share, with a total value of $198,000.00. Following the completion of the transaction, the chief operating officer now directly owns 502,295 shares of the company's stock, valued at $1,105,049. Learn More on Paul Edward Kelly's trading history.
Who are Relmada Therapeutics' active insiders?: Relmada Therapeutics' insider roster includes Charles Casamento (Director), Chuck Ence (Chief Accounting and Compliance Officer), Paul Kelly (COO), Maged Shenouda (CFO), and Sergio Traversa (CEO). Learn More on Relmada Therapeutics' active insiders.
Are insiders buying or selling shares of Relmada Therapeutics?: In the last twelve months, Relmada Therapeutics insiders bought shares 9 times. They purchased a total of 1,366,626 shares worth more than $1,931,592.25. The most recent insider tranaction occured on December, 15th when CFO Maged Shenouda bought 11,665 shares worth more than $48,059.80. Insiders at Relmada Therapeutics own 20.7% of the company. Learn More about insider trades at Relmada Therapeutics.
Information on this page was last updated on 12/15/2025.

Paul Edward Kelly Insider Trading History at Relmada Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/5/2025	Buy	90,000	$2.20	$198,000.00	502,295
5/16/2025	Buy	200,000	$0.43	$86,000.00	412,295
4/4/2022	Sell	10,000	$30.04	$300,400.00	187,295
3/9/2021	Sell	5,000	$35.71	$178,550.00	172,295
2/8/2021	Sell	1,500	$35.04	$52,560.00	165,864
1/27/2021	Sell	5,000	$32.46	$162,300.00	152,295
1/25/2021	Sell	1,300	$35.27	$45,851.00	151,380
1/22/2021	Sell	2,100	$3,042.03	$6,388,263.00	151,380
10/18/2019	Buy	5,000	$30.00	$150,000.00
5/14/2019	Buy	100,000	$1.50	$150,000.00
12/11/2018	Buy	5,000	$1.21	$6,050.00
10/12/2018	Buy	150,000	$0.90	$135,000.00

Paul Edward Kelly Buying and Selling Activity at Relmada Therapeutics

Relmada Therapeutics Company Overview

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Today's Range

Now: $6.59

$6.19

$6.74

50 Day Range

MA: $4.58

$3.55

$7.01

2 Week Range

Now: $6.59

$0.24

$7.51

Volume

1,399,607 shs

Average Volume

1,556,302 shs

Market Capitalization

$483.10 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72